• Home
• Resources
  • Abstracts
  • Audio CDs
  • Books
  • Case Discussions
  • CME
  • Consultant Articles
  • Interviews
  • Meetings
  • Organizations
  • Products
  • Studies
  • Video
  • Websites
• Blog Topics
  • Allergies
  • Cancer
  • Cataract
  • Conjunctivitis
  • Cornea
  • Diabetes
  • Dry Eye
  • Glaucoma
  • Industry News
  • LASIK
  • Macular Degeneration
  • NeuroOphthalmology
  • New Technologies
  • Optic Nerve
  • Pediatrics
  • Plastics
  • Practice Tips
  • Refractive
  • Research
  • Retina
  • Stem Cell Therapies
• Discussions
• For Patients
  • Patient Education
  • Patient Questions
  • Questions Answered
• Find a Doctor

CMS Reverses the Reimbursement for AVASTIN

By Irv Arons

In a move in response to the pressure of the AAO and several other ophthalmic groups, the CMS has rescinded Code Q2024 about reimbursement for Avastin. Reimbursement now reverts back to the original pre-October 1st  policy of $50 per dose.

For more, see my writeup posted this morning on my online Journal.

You might also enjoy...

• Update on Avastin vs. Lucentis: CMS Ups the Ante
• CMS Reverses Position on Avastin for AMD
• Which is More Effective – Avastin or Lucentis?
• The London Project To Cure Blindness – An Update
• Is Iluvien From Alimera Sciences the Future of Ophthalmic Drug Delivery?

Comments

Jump down to form below to submit your own comments

Google XML Sitemap · Copyright © 2010 EyeDocNews · Terms of Use · Disclaimer